Dianthus Therapeutics (DNTH) Stock Analysis & AI Equity Report
Dianthus Therapeutics (DNTH) overview
Dianthus Therapeutics (DNTH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2.0m and operating profit of USD -178m; the year-end share price was 41.21 USD and market capitalisation was USD 1,781m. Dianthus Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Dianthus Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its clinical candidates include claseprubart, a monoclonal antibody designed to selectively inhibit active C1s in the classical complement pathway, and DNTH212, a fusion protein targeting plasmacytoid dendritic cells and B-cell function. Claseprubart is being studied in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
Generate the Dianthus Therapeutics report
Dianthus Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Dianthus Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Dianthus Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.